CN105030940A - Pharmaceutical composition for reducing blood glucose and application thereof - Google Patents
- ️Wed Nov 11 2015
CN105030940A - Pharmaceutical composition for reducing blood glucose and application thereof - Google Patents
Pharmaceutical composition for reducing blood glucose and application thereof Download PDFInfo
-
Publication number
- CN105030940A CN105030940A CN201510446813.8A CN201510446813A CN105030940A CN 105030940 A CN105030940 A CN 105030940A CN 201510446813 A CN201510446813 A CN 201510446813A CN 105030940 A CN105030940 A CN 105030940A Authority
- CN
- China Prior art keywords
- extract
- parts
- pharmaceutical composition
- pueraria
- ethanol Prior art date
- 2015-07-27 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title claims abstract description 10
- 210000004369 blood Anatomy 0.000 title claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title description 2
- 239000008103 glucose Substances 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 20
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241000219780 Pueraria Species 0.000 claims abstract 10
- 239000012675 alcoholic extract Substances 0.000 claims abstract 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract 3
- 241000219781 Pueraria montana var. lobata Species 0.000 claims abstract 3
- 239000000469 ethanolic extract Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000002481 ethanol extraction Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 241000218202 Coptis Species 0.000 claims 5
- 235000002991 Coptis groenlandica Nutrition 0.000 claims 5
- 241000037740 Coptis chinensis Species 0.000 claims 4
- 239000006286 aqueous extract Substances 0.000 claims 4
- 238000002791 soaking Methods 0.000 claims 3
- 238000000874 microwave-assisted extraction Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000002137 ultrasound extraction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 7
- 229930013930 alkaloid Natural products 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000008838 gegenqinlian Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002879 macerating effect Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种降血糖的药物组合物，它是由下述重量配比的原料制备而成的制剂：黄连醇提物1.5～3.0份、黄连水提物1.0份、葛根醇提物3.3～5.6份、葛根水提物3.3～5.6份，各原料重量配比以干燥品计。本发明还提供了该药物组合物的用途。本发明提供的药物组合物，能够有效降低糖尿病患者空腹血糖值，具有良好的降血糖功效，可用于糖尿病(特别是2型糖尿病)的预防或治疗。The invention provides a drug composition for lowering blood sugar, which is a preparation prepared from the following raw materials in weight ratio: 1.5-3.0 parts of Coptidis rhizome alcoholic extract, 1.0 parts of Coptidis rhizome water extract, 3.3 parts of Pueraria rhizome alcoholic extract ～5.6 parts, 3.3～5.6 parts of kudzu root water extract, the weight ratio of each raw material is calculated on the dry product. The invention also provides the application of the pharmaceutical composition. The pharmaceutical composition provided by the invention can effectively reduce the fasting blood sugar level of diabetic patients, has a good hypoglycemic effect, and can be used for the prevention or treatment of diabetes (especially type 2 diabetes).
Description
Technical field
The present invention relates to a kind of hypoglycemic medical composition and its use.
Background technology
GEGEN QINLIAN TANG, is made up of Radix Puerariae, Radix Scutellariae, Rhizoma Coptidis and Radix Glycyrrhizae four taste Chinese medicine, has effect of expelling pathogen from the exterior and clearing up internal heat.Clinical and modern medicines research shows in a large number, and GEGEN QINLIAN TANG is widely used in the treatment of diabetes, and effect is similar with metformin.
Patent publication No.: CN102895342A, this patent application has carried out Dismemberment study to GEGEN QINLIAN TANG, and find when use Radix Puerariae: during Rhizoma Coptidis=8:3, its prescription just can reach the hypoglycemic activity of the full side of GEGEN QINLIAN TANG; Meanwhile, this patent application also represents, by Radix Puerariae total flavones: Rhizoma Coptidis total alkaloids=1.12:0.5277 combinationally uses, and its drug activity is slightly better than the direct compatibility of medical material and decocts.
Can in Radix Puerariae, Rhizoma Coptidis two taste medical material, find more rational compatibility occupation mode, be research purpose of the present invention.
Summary of the invention
The object of the present invention is to provide a kind of new hypoglycemic medicine composition based on Radix Puerariae, Rhizoma Coptidis extract, another object of the present invention is to the purposes that said composition is provided.
Particularly, the invention provides the pharmaceutical composition of a kind of prevention or treatment diabetes, its crude drug is made up of the component of following proportioning:
Rhizoma Coptidis ethanol extract 1.5 ~ 3.0 parts, Rhizoma Coptidis water extract 1.0 parts, Radix Puerariae ethanol extract 3.3 ~ 5.6 parts, Radix Puerariae water extract 3.3 ~ 5.6 parts, each raw material weight proportioning is in dry product;
Wherein, each extract prepares by the following method:
Rhizoma Coptidis ethanol extract is Rhizoma Coptidis 80 ~ 95%v/v ethanol extraction;
Rhizoma Coptidis water extract is after Rhizoma Coptidis 80 ~ 95%v/v ethanol extraction, the water extract of medicinal residues;
Radix Puerariae ethanol extract is Radix Puerariae 80 ~ 95%v/v ethanol extraction;
Radix Puerariae water extract is after Radix Puerariae 80 ~ 95%v/v ethanol extraction, the water extract of medicinal residues.
Further, described weight proportion is as follows:
Rhizoma Coptidis ethanol extract 2.5 parts, Rhizoma Coptidis water extract 1.0 parts, Radix Puerariae ethanol extract 3.3 ~ 4.1 parts, Radix Puerariae water extract 3.3 ~ 4.1 parts.
Further, described weight proportion is as follows:
Rhizoma Coptidis ethanol extract 2.5 parts, Rhizoma Coptidis water extract 1.0 parts, Radix Puerariae ethanol extract 4.1 parts, Radix Puerariae water extract 4.1 parts.The present invention studies discovery, and under this proportioning, the hypoglycemic activity of extract significantly improves, and is significantly better than other each proportioning groups.
The concentration of alcohol used in the present invention's detailed description of the invention is 95%v/v, and based on the similarity of high concentration ethanol polarity, the present invention also advises that the minimum 80%v/v ethanol that can use is as Extraction solvent.Certainly, if the concordance of guarantee and pharmacodynamic results of the present invention, when considering error, concentration of alcohol uses 90 ~ 95%v/v.
Wherein, the extracting mode of ethanol extraction Rhizoma Coptidis or Radix Puerariae is selected from backflow, ultrasonic, warm macerating, merceration or microwave radiation exaraction.
Wherein, in Rhizoma Coptidis water extract or Radix Puerariae water extract preparation process, the water extraction mode of medicinal residues is selected from decoction, warm macerating, ultrasonic or microwave radiation exaraction.
Wherein, in the present invention's detailed description of the invention, pharmaceutical composition of the present invention have chosen through gastrointestinal absorption dosage form.
Present invention also offers the purposes of aforementioned pharmaceutical compositions in the hypoglycemic medicine of preparation.
Further, described medicine is the medicine of prevention or treatment diabetes.
Further, described diabetes are type 2 diabetes mellitus.
Pharmaceutical composition provided by the invention, can effectively reduce diabetics fasting blood sugar, have good effect of lowering blood sugar, can be used for prevention or the treatment of diabetes (particularly type 2 diabetes mellitus).The present invention has carried out further further investigation to each extract proportioning, have unexpectedly discovered that " Rhizoma Coptidis ethanol extract 2.5 parts, Rhizoma Coptidis water extract 1.0 parts, Radix Puerariae ethanol extract 4.1 parts, Radix Puerariae water extract 4.1 parts " this proportion relation is active abnormal good, significantly be better than other each proportioning groups (p<0.05), comprise the best crude drug proportioning group (the present invention 1 group) in number of patent application CN102895342A; Meanwhile, this proportioning is also significantly better than Rhizoma Coptidis total alkaloids in CN102895342A and Radix Puerariae total flavones proportioning group (p<0.05).Obviously, this result is beyond the expectation of those skilled in the art to prior art.
Detailed description of the invention
Embodiment 1 extract preparation of the present invention
(1) preparation of Rhizoma Coptidis ethanol extract: get Rhizoma Coptidis, adds 95%v/v alcohol reflux 3 times, and filter, medicinal residues are for subsequent use, merge extractive liquid, reclaims ethanol, and dry, obtain Rhizoma Coptidis ethanol extract, after measured, paste-forming rate is about 18%.
(2) preparation of Rhizoma Coptidis water extract: get the medicinal residues in step (1), decoct with water 3 times, filters, merging filtrate, concentrated, and dry, obtain Rhizoma Coptidis water extract, after measured, paste-forming rate is about 12%.
(3) preparation of Radix Puerariae ethanol extract: get Rhizoma Coptidis, adds 95%v/v alcohol reflux 3 times, and filter, medicinal residues are for subsequent use, merge extractive liquid, reclaims ethanol, and dry, obtain Radix Puerariae ethanol extract, after measured, paste-forming rate is about 15%.
(4) preparation of Radix Puerariae water extract: get the medicinal residues in step (3), decoct with water 3 times, filters, merging filtrate, concentrated, and dry, obtain Radix Puerariae water extract, after measured, paste-forming rate is about 11%.
(5) preparation of the present composition: take raw material by following proportioning: Rhizoma Coptidis ethanol extract: Rhizoma Coptidis water extract: Radix Puerariae ethanol extract: Radix Puerariae water extract=2.5:1:4.1:4.1, add appropriate microcrystalline Cellulose, after mixing, dry, encapsulated, obtain capsule.
The recipe determination experiment of embodiment 2 pharmaceutical composition of the present invention
ICR mice, male and female half and half, weight 20-22g.Random packet (grouping situation is in table 1), often organize 10, the proportioning for each extract of the present invention is screened.Mice fasting 18h before test, lumbar injection STZ buffer 100mg/Kg in morning next day (blank group injection equivalent 0.1mol/L citric acid-sodium citrate buffer), grouping and dosage gastric infusion is designed by table 1, every day 1 time, continuous 14d, while administration, give the high sugared high salt emulsion 0.4ml/ of high fat only copy type 2 diabetes mellitus mouse model, blank group gives normal feedstuff and feeds.40min after the administration of 14d last, gets blood, measures mice fasting glucose (FBG).
Table 1
Note: Rhizoma Coptidis ethanol extract is abbreviated as HC, Rhizoma Coptidis water extract is abbreviated as HS, and Radix Puerariae ethanol extract is abbreviated as GC, and Radix Puerariae water extract is abbreviated as GS; In CN102895342A, the preparation method of Rhizoma Coptidis total alkaloids and Radix Puerariae total flavones is see its patent application 32 ~ 34 sections.
A, compares p<0.05 with model group; Aa, compares p<0.01 with model group;
B, compares p<0.05 with " HC:HS:GC:GS=2.5:1:4.1:4.1 " group;
C, compares p<0.05 with positive controls.
As seen from the results in Table 1:
(1) compared with model group, all there were significant differences (p<0.01) for the FBG value of the present invention's 1 ~ 9 group of compositions, namely represents, each compositions of the present invention all effectively can reduce the fasting blood sugar of type 2 diabetes mellitus model.
(2) what give in prior art matched group is best of breed thing in number of patent application CN102895342A, be made up of the extract of Radix Puerariae, Rhizoma Coptidis, if be converted into crude drug, both should be Rhizoma Coptidis at proportioning: Radix Puerariae=3:8, identical with the crude drug proportioning of the present invention 1 group.But compare discovery by 1 group with prior art matched group, two kinds of medicines are carried out alcohol water pair and propose rear use by the present invention 1 group, and its drug action outline is better than combinationally using of both single extracts.
(3) in number of patent application CN102895342A, table 2 result shows, Rhizoma Coptidis: Radix Puerariae=3:8 is the optimum proportioning of compatibility between two, Rhizoma Coptidis: Radix Puerariae=2:9,5:6 is slightly inferior to optimum proportioning.The present invention is according to extract paste-forming rate, above-mentioned three kinds of proportionings have been converted into the proportioning of extract, extract is compared (see 1 ~ 3 group), wherein, HC:HS:GC:GS=1.5:1:3.3:2.4 (being equivalent to Rhizoma Coptidis: Radix Puerariae=3:8) is still best group, HC:HS:GC:GS=1.5:1:5.6:4.1 (being equivalent to Rhizoma Coptidis: Radix Puerariae=2:9) hypoglycemic activity is slightly weak, and HC:HS:GC:GS=1.5:1:1.5:1.1 (being equivalent to Rhizoma Coptidis: Radix Puerariae=5:6) hypoglycemic activity takes second place.As can be seen here, the present invention is combined by the two extract of alcohol water, equally also verifies Rhizoma Coptidis: Radix Puerariae=3:8 is better than the hypoglycemic activity of 2:9,5:6, consistent with number of patent application CN102895342A result.
Except the extract combination mode after converting above by existing crude drug proportioning, each extract consumption has also been carried out larger adjustment by the present invention, for confirmation according to Rhizoma Coptidis: whether the extractive composition proportioning (1 group) that Radix Puerariae=3:8 provides is exactly optimum composition method.But experimental result is really not so.
Find in experiment:
1,4,5 groups are compared: after being improved by Rhizoma Coptidis ethanol extract consumption (4 groups, HC:HS:GC:GS=2.5:1:3.3:2.4), compared with 1 group, its hypoglycemic activity also slightly improves; After being reduced by Rhizoma Coptidis ethanol extract consumption (5 groups, HC:HS:GC:GS=0.5:1:3.3:2.4), compared with 1 group, hypoglycemic activity reduces.
4,6 ~ 9 groups are compared: after reduction Radix Puerariae ethanol extract consumption (6 groups, HC:HS:GC:GS=2.5:1:2.4:2.4), compared with 4 groups, its hypoglycemic activity slightly reduces; After rising Radix Puerariae water extract consumption (7 groups, HC:HS:GC:GS=2.5:1:3.3:3.3), compared with 4 groups, its hypoglycemic activity slightly improves; Raise (8 groups, HC:HS:GC:GS=2.5:1:4.1:4.1) after Radix Puerariae ethanol extract and water extract consumption, compared with 4 groups, its hypoglycemic activity significantly improves simultaneously; But on the basis of the 8th group, then raise Radix Puerariae ethanol extract and water extract consumption (9 groups, HC:HS:GC:GS=2.5:1:5.6:5.6), then activity is lower than the 8th group on the contrary, suitable with the 4th group.
Although there was no significant difference between the 7th group and 8 groups, but, 8 groups have better blood sugar lowering trend, and it is comparatively close with the effect of metformin group, there was no significant difference (p>0.05) between the two, and 7 groups of blood sugar reducing functions are starkly lower than metformin, have significant difference (p<0.05) between the two, as can be seen here, the hypoglycemic activity of the 8th group is better than the 7th group.
Comprehensive the above results is known, the present invention the 8th assembly 5 (HC:HS:GC:GS=2.5:1:4.1:4.1), hypoglycemic activity is significantly better than other each proportioning groups (p<0.05), comprising the best crude drug proportioning group (the present invention 1 group) in number of patent application CN102895342A, is optimum proportioning of the present invention.Meanwhile, the 8th assembly 5 activity is also significantly better than Rhizoma Coptidis total alkaloids in CN102895342A and Radix Puerariae total flavones proportioning group (p<0.05).As can be seen here, the present invention unexpectedly screens and obtains Rhizoma Coptidis, the ethanol extract of Radix Puerariae, the optimum proportioning relation of water extract, in this proportion relation and prior art (number of patent application CN102895342A), the technology of best compatibility is enlightened and is not had relatedness, beyond the expection of research worker of the present invention.
Claims (10)
1.一种降血糖的药物组合物，其特征在于:其原料药由如下配比的组分组成：1. a hypoglycemic pharmaceutical composition, is characterized in that: its crude drug is made up of the component of following proportioning: 黄连醇提物1.5～3.0份、黄连水提物1.0份、葛根醇提物3.3～5.6份、葛根水提物3.3～5.6份，各原料重量配比以干燥品计；1.5-3.0 parts of Coptis chinensis alcoholic extract, 1.0 parts of Coptis chinensis water extract, 3.3-5.6 parts of Pueraria rhizome alcoholic extract, 3.3-5.6 parts of Pueraria rhizome water extract, the weight ratio of each raw material is calculated as dry product; 其中，各提取物由如下方法制备得到：Wherein, each extract is prepared by the following method: 黄连醇提物是黄连80～95％v/v乙醇提取物；The alcoholic extract of Coptidis rhizome is 80-95% v/v ethanol extract of Coptidis rhizome; 黄连水提物是黄连80～95％v/v乙醇提取后，药渣的水提物；The water extract of Coptis chinensis is the water extract of medicinal dregs after 80-95% v/v ethanol extraction of Coptis chinensis; 葛根醇提物是葛根80～95％v/v乙醇提取物；The ethanol extract of Pueraria lobata is 80-95% v/v ethanol extract of Pueraria lobata; 葛根水提物是葛根80～95％v/v乙醇提取后，药渣的水提物。The pueraria root water extract is the water extract of the medicinal dregs after the pueraria root is extracted with 80-95% v/v ethanol. 2.根据权利要求1所述的药物组合物，其特征在于:所述重量配比如下：2. pharmaceutical composition according to claim 1, is characterized in that: described weight ratio is as follows: 黄连醇提物2.5份、黄连水提物1.0份、葛根醇提物3.3～4.1份、葛根水提物3.3～4.1份。2.5 parts of alcoholic extract of coptis, 1.0 part of aqueous extract of coptis, 3.3-4.1 parts of alcoholic extract of pueraria, 3.3-4.1 parts of aqueous extract of pueraria. 3.根据权利要求2所述的药物组合物，其特征在于:所述重量配比如下：3. pharmaceutical composition according to claim 2, is characterized in that: described weight ratio is as follows: 黄连醇提物2.5份、黄连水提物1.0份、葛根醇提物4.1份、葛根水提物4.1份。2.5 parts of alcoholic extract of coptis, 1.0 part of aqueous extract of coptis, 4.1 parts of alcoholic extract of Pueraria root, and 4.1 parts of aqueous extract of Pueraria rhizome. 4.根据权利要求1所述的药物组合物，其特征在于:所述乙醇浓度为90～95％v/v，优选为95％v/v。4. pharmaceutical composition according to claim 1, is characterized in that: described ethanol concentration is 90～95% v/v, is preferably 95% v/v. 5.根据权利要求1所述的药物组合物，其特征在于:乙醇提取黄连或葛根的提取方式选自回流、超声、温浸、冷浸或微波辅助提取。5. The pharmaceutical composition according to claim 1, characterized in that: the extraction mode of ethanol extraction of Coptis Rhizoma or Radix Puerariae is selected from reflux, ultrasonic, warm soaking, cold soaking or microwave-assisted extraction. 6.根据权利要求1所述的药物组合物，其特征在于:黄连水提物或葛根水提物制备过程中，药渣的水提方式选自煎煮、温浸、超声或微波辅助提取。6. The pharmaceutical composition according to claim 1, characterized in that: in the preparation process of Coptidis Rhizoma water extract or Pueraria root water extract, the water extraction method of medicinal dregs is selected from decoction, warm soaking, ultrasonic or microwave-assisted extraction. 7.根据权利要求1～6任意一项所述的药物组合物，其特征在于：所述药物组合物的制剂为经胃肠道吸收剂型。7. The pharmaceutical composition according to any one of claims 1-6, characterized in that: the preparation of the pharmaceutical composition is a dosage form absorbed through the gastrointestinal tract. 8.权利要求1～7任意一项所述药物组合物在制备降血糖的药物中的用途。8. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a drug for lowering blood sugar. 9.根据权利要求8所述的用途，其特征在于：所述药物是预防或治疗糖尿病的药物。9. The use according to claim 8, characterized in that: the medicine is a medicine for preventing or treating diabetes. 10.根据权利要求9所述的用途，其特征在于：所述糖尿病为2型糖尿病。10. The use according to claim 9, characterized in that: the diabetes is type 2 diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446813.8A CN105030940B (en) | 2015-07-27 | 2015-07-27 | A kind of hypoglycemic medical composition and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446813.8A CN105030940B (en) | 2015-07-27 | 2015-07-27 | A kind of hypoglycemic medical composition and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105030940A true CN105030940A (en) | 2015-11-11 |
| CN105030940B CN105030940B (en) | 2018-02-23 |
Family
ID=54438303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510446813.8A Expired - Fee Related CN105030940B (en) | 2015-07-27 | 2015-07-27 | A kind of hypoglycemic medical composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030940B (en) |
Cited By (4)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497051A (en) * | 2015-12-09 | 2016-04-20 | 陕西中医药大学 | Pharmaceutical formula capable of lowering blood glucose and experiment method of pharmaceutical formula |
| CN105902610A (en) * | 2016-05-31 | 2016-08-31 | 湖北老乡农业科技有限公司 | Blood sugar lowering tablet and preparation method thereof |
| CN108112996A (en) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | A kind of alimentation composition for controlling diabetes B crowd hyperglycaemia and improving immunity |
| CN112603950A (en) * | 2021-01-14 | 2021-04-06 | 王芝凯 | Medicinal beverage for treating diabetes and its preparation method |
Citations (1)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895342A (en) * | 2011-10-14 | 2013-01-30 | 西南交通大学 | Medicinal composition for preventing or/and treating diabetes mellitus and application of medicinal composition |
-
2015
- 2015-07-27 CN CN201510446813.8A patent/CN105030940B/en not_active Expired - Fee Related
Patent Citations (1)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895342A (en) * | 2011-10-14 | 2013-01-30 | 西南交通大学 | Medicinal composition for preventing or/and treating diabetes mellitus and application of medicinal composition |
Non-Patent Citations (3)
* Cited by examiner, † Cited by third party| Title |
|---|
| 李佳川等: "葛根芩连汤有效组分"止消渴"药效作用研究", 《中药材》 * |
| 王霜等: "基于基线等比增减设计法优选葛根-黄连抗消渴最佳配比", 《中国实验方剂学杂志》 * |
| 王霜等: "葛根黄连有效组分在大鼠体内药代动力学研究", 《西南民族大学学报》 * |
Cited By (6)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497051A (en) * | 2015-12-09 | 2016-04-20 | 陕西中医药大学 | Pharmaceutical formula capable of lowering blood glucose and experiment method of pharmaceutical formula |
| CN105497051B (en) * | 2015-12-09 | 2018-07-17 | 陕西中医药大学 | A kind of hypoglycemic pharmaceutical formulation and its experimental method |
| CN105902610A (en) * | 2016-05-31 | 2016-08-31 | 湖北老乡农业科技有限公司 | Blood sugar lowering tablet and preparation method thereof |
| CN108112996A (en) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | A kind of alimentation composition for controlling diabetes B crowd hyperglycaemia and improving immunity |
| CN108112996B (en) * | 2017-12-12 | 2021-02-05 | 法尔玛国际健康管理有限公司 | Nutritional composition for controlling hyperglycemia and improving immunity of type 2 diabetes mellitus people |
| CN112603950A (en) * | 2021-01-14 | 2021-04-06 | 王芝凯 | Medicinal beverage for treating diabetes and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105030940B (en) | 2018-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028900B (en) | 2012-03-14 | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof |
| CN101028507A (en) | 2007-09-05 | Chinese-medicinal composition for treating asthma |
| CN105030940A (en) | 2015-11-11 | Pharmaceutical composition for reducing blood glucose and application thereof |
| CN105456622A (en) | 2016-04-06 | Traditional Chinese medicine composition and preparation for treating impaired glucose regulation and preparation method thereof |
| CN103784933A (en) | 2014-05-14 | Recurrent oral ulcer power |
| CN102283913B (en) | 2013-03-27 | Radix aconiti carmichaeli extract and application thereof |
| CN104398771B (en) | 2017-11-10 | A kind of Chinese medicine composition for treating diabetes |
| CN103330868B (en) | 2015-03-11 | Intestinal tract replenishing liquid for chronic renal failure |
| CN105030939B (en) | 2018-01-19 | A kind of hypoglycemic granule and capsule |
| CN1160108C (en) | 2004-08-04 | Medicine for treating cholecystitis and its preparing process |
| CN103211996B (en) | 2014-07-09 | Preparation method of traditional Chinese medicine for treating diabetes mellitus |
| CN103432420B (en) | 2015-12-02 | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method |
| CN102580024A (en) | 2012-07-18 | Composition for treating cardiovascular diseases |
| CN1813819B (en) | 2011-04-27 | Hedgehog hydnum fruiting body or hyphostroma, culture extract, formulation and preparing method |
| CN103566227B (en) | 2015-09-16 | A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof |
| CN103230552B (en) | 2014-08-27 | Traditional Chinese medicine for treating diabetes mellitus |
| CN103341095B (en) | 2015-04-29 | Clysis liquid used for chronic renal failure |
| CN103585495B (en) | 2015-06-10 | Capsule for treating diabetic kidney damage |
| CN106581236A (en) | 2017-04-26 | Medicinal composition for promoting gastric motility, and preparation method and application thereof |
| CN104707106A (en) | 2015-06-17 | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof |
| CN104352748A (en) | 2015-02-18 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
| CN103877374B (en) | 2016-06-15 | A kind of for Chinese medicine treating diabetes and preparation method thereof |
| CN104436001A (en) | 2015-03-25 | Traditional Chinese medicine composition for treating gall-stone as well as preparation method and application |
| CN104189857A (en) | 2014-12-10 | Medicament for treating cardiovascular and cerebrovascular diseases |
| CN104027450B (en) | 2016-01-20 | A kind of Chinese medicine composition for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 2015-11-11 | C06 | Publication | |
| 2015-11-11 | PB01 | Publication | |
| 2015-12-09 | C10 | Entry into substantive examination | |
| 2015-12-09 | SE01 | Entry into force of request for substantive examination | |
| 2018-02-23 | GR01 | Patent grant | |
| 2018-02-23 | GR01 | Patent grant | |
| 2024-06-25 | CF01 | Termination of patent right due to non-payment of annual fee | |
| 2024-06-25 | CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180223 |